Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 31, 2007

Cellzome and J&JPRD Extend Alzheimer’s Partnership

  • Cellzome, Ortho-McNeil Pharmaceutical, and its affiliate Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) extended their joint research program aimed at identifying new medicines for the treatment of Alzheimer’s disease for one year.

    First announced in March 2005, the collaboration provides J&JPRD with Cellzome’s Amyloid Precursor Protein processing pathway map containing new drug targets, its chemical proteomics technology, and novel small molecules targeted at Gamma Secretase.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »